← Back to Search

Anti-malarial drug

Hydroxychloroquine for Hydroxychloroquine (HCQPreP Trial)

Phase 3
Waitlist Available
Research Sponsored by Louisiana State University Health Sciences Center in New Orleans
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

HCQPreP Trial Summary

This trial will study if the drug hydroxychloroquine can help prevent COVID-19 infection in healthcare workers.

Eligible Conditions
  • Hydroxychloroquine
  • Coronavirus
  • COVID-19
  • Prophylaxis
  • Health Care Worker

HCQPreP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of symptomatic COVID-19 infection in healthcare workers
Secondary outcome measures
Absenteeism from work due to COVID-19
Severity of COVID-19 infection

Side effects data

From 2016 Phase 3 trial • 217 Patients • NCT02057250
13%
Upper respiratory tract infection
6%
Neutropenia
6%
Sinusitis
5%
Alanine aminotransferase increased
5%
Urinary tract infection
4%
Injection site erythema
4%
Accidental overdose
4%
Bronchitis
3%
Injection site pruritus
2%
Thrombocytopenia
2%
Nasopharyngitis
2%
Contusion
1%
Arthralgia
1%
Anaemia
1%
Lumbar spinal stenosis
1%
Leukopenia
1%
Coronary artery occlusion
1%
Wolff-Parkinson-White syndrome
1%
Transient ischaemic attack
1%
Vertebrobasilar insufficiency
1%
Chronic obstructive pulmonary disease
1%
Small intestinal obstruction
1%
Nephrolithiasis
1%
Cataract
1%
Thrombophlebitis superficial
1%
Vomiting
1%
Endometrial hyperplasia
1%
Traumatic arthritis
1%
Hypertension
1%
Pneumonia
1%
Pancreatic carcinoma metastatic
1%
Osteoarthritis
1%
Rheumatoid lung
1%
Pharyngitis
1%
Femoral neck fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sarilumab 150 mg by PFS (Extension Phase)
Sarilumab 150 mg by AID (AID Assessment Phase)
Sarilumab 150 mg by PFS (AID Assessment Phase)
Sarilumab 200 mg by PFS (AID Assessment Phase)
Sarilumab 200 mg by AID (AID Assessment Phase)

HCQPreP Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: HydroxychloroquineExperimental Treatment1 Intervention
Hydroxychloroquine loading dose will be given as 400mg for two doses 12 hours apart. This will then be followed by maintenance dosing of 200mg twice weekly for the remainder of the trial.
Group II: PlaceboPlacebo Group1 Intervention
An identical placebo will be administered on an identical dosing interval and frequency.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hydroxychloroquine
FDA approved

Find a Location

Who is running the clinical trial?

Louisiana State University Health Sciences Center in New OrleansLead Sponsor
114 Previous Clinical Trials
42,501 Total Patients Enrolled
Lafayette General HealthOTHER
University of Louisiana at LafayetteOTHER
2 Previous Clinical Trials
16 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)
Ann Chauffe 2020. "Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04363450.
All > Covid
~340 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top